Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue Arthritis Research & Therapy Année : 2023

Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study

Stefan Siebert
  • Fonction : Auteur
Paul Bergmans
  • Fonction : Auteur
Kurt de Vlam
  • Fonction : Auteur
Elisa Gremese
  • Fonction : Auteur
Beatríz Joven-Ibáñez
  • Fonction : Auteur
Tatiana V Korotaeva
  • Fonction : Auteur
Frederic Lavie
  • Fonction : Auteur
Wim Noël
  • Fonction : Auteur
Michael T Nurmohamed
  • Fonction : Auteur
Petros P Sfikakis
  • Fonction : Auteur
Mohamed Sharaf
  • Fonction : Auteur
Elke Theander
  • Fonction : Auteur
Josef S Smolen
  • Fonction : Auteur

Résumé

Abstract Background To evaluate the real-world effect of the IL-12/23 inhibitor ustekinumab or of a tumour necrosis factor inhibitor (TNFi) on patient-reported outcomes (PRO) and their association with effectiveness endpoints in psoriatic arthritis (PsA) patients over 3 years. Methods In PsABio (NCT02627768), a prospective, observational study, patients with PsA that were prescribed first- to third-line ustekinumab or a TNFi, and remained on that drug for 3 years, were analysed for change in baseline in PROs (EuroQol-5 dimensions health state VAS [EQ-5D VAS], 12-item Psoriatic Arthritis Impact of Disease questionnaire [PsAID-12; range 0–10], Work Productivity and Activity Impairment for Psoriatic Arthritis questionnaire [WPAI; results expressed as a percentage for each domain]), and the association between PROs and WPAI with effectiveness endpoints, clinical disease activity index for psoriatic arthritis (cDAPSA), low disease activity (LDA)/remission, minimal disease activity (MDA) and very low disease activity (VLDA). Results In 437 patients (mean age 49.1 years, 47.8% female), at 3 years, ustekinumab and TNFi treatment led to comparable improvements in EQ-5D VAS; mean change from baseline (95% confidence intervals [CI]) was 11.0 (6.5; 15.4) and 18.9 (14.0; 23.9), respectively. Both groups improved PsAID-12 after 3 years; mean change from baseline (95% CI) was −2.9 (−3.2; −2.5) and −3.5 (−3.9; −3.2), respectively. At baseline, due to their PsA, TNFi-treated patients had lower work productivity compared to ustekinumab-treated patients; mean productivity reduction (95% CI) was 58.8 [52.4; 65.2] and 43.3 [35.6; 51.1]. Over 3 years, TNFi-treated patients had a greater improvement in work productivity compared to ustekinumab-treated patients, ultimately leaving work productivity to be comparable between groups; mean improvement (95% CI) was 44.5% (38.4; 50.6) and 24.9% (15.8; 34.0), respectively. A similar trend was observed in activity impairment. Patients in both treatment groups who achieved effectiveness endpoints, cDAPSA LDA/remission, MDA, and VLDA had greater improvement in PROs and WPAI than patients who did not achieve these endpoints. Conclusions At 3 years, improvements in PROs following ustekinumab or TNFi treatment were generally comparable; however, TNFi-treated patients achieved a greater improvement in work productivity, although this group started from a lower baseline. Achievement of effectiveness endpoints, independent of treatment group, also improved PROs. Trial registration ClinicalTrials.gov, NCT02627768. Registered on 11 December 2015
Fichier principal
Vignette du fichier
2023 Gossec ART improvement in pros and work after 3 yrs PsABio.pdf (3.57 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence
Domaine public

Dates et versions

hal-04217803 , version 1 (26-09-2023)

Licence

Domaine public

Identifiants

Citer

Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, et al.. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study. Arthritis Research & Therapy, 2023, 25 (1), pp.109. ⟨10.1186/s13075-023-03058-y⟩. ⟨hal-04217803⟩
6 Consultations
7 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More